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1. Introduction 
The varicella-zoster virus (VZV or Human Herpesvirus-3) is a member of the human 
herpesvirus family. Identified as the causative agent of chickenpox and shingles, VZV is a 
significant pathogen in the United States, infecting over 90% of the US population 
(Abendroth & Arvin, 1999). Primary VZV infections generally occur during childhood and 
result in a relatively benign illness termed varicella (chickenpox). However, like all 
herpesviruses, VZV will establish latency in the host’s sensory neurons. This occurs 
specifically in the trigeminal ganglia and dorsal root ganglia (Arvin, 1996; Gilden et al., 
2000), where the virus can hide from the immune system for years and often a lifetime.  
Reactivation of this virus with increasing age or immunosuppression results in herpes 
zoster (shingles). Herpes zoster is a more painful, neurocutaneous infection associated with 
acute or chronic neuropathic pain and a significant incidence of post-herpetic neuralgia, a 
complication causing many patients to continue suffering excruciating pain, lasting 
anywhere from months to years after infection due to the resulting nerve damage (Cohen et 
al, 2007). This not only greatly increases the cost of medical care, but also significantly 
compromises the quality of life in the elderly (Pickering & Leplege, 2010; Opstelten et al., 
2010; Burgoon et al, 1957).  
1.1 The varicella vaccine 
In the early 1970s, Japanese researchers isolated a VZV sample from the blood of a small 
boy. Through serial passage in cell culture, scientists were able to successfully develop the 
first live attenuated varicella vaccine (Takahashi et al., 1974; Arvin, 2001; Gershon, 2001). 
The vaccine strain was termed the Japanese Oka varicella virus (v-Oka). By 1995, this 
chickenpox vaccine was introduced to the United States and quickly recommended for 
vaccination in all children. Since then, chickenpox incidence in the US has dramatically 
declined; the effectiveness of this vaccine is estimated to be between 72% and 98% 
(Hambleton & Gershon, 2005). Nevertheless, outbreaks of chickenpox are still ever-present. 
Furthermore, the vaccine may indirectly increase the occurrence of herpes zoster in the 
elderly population by lessening the number of natural infections, and therefore lowering the 
exposure to wild-type VZV that would boost natural immunity (Arvin, 2001; Galea et al, 
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2008; Volpi, 2005). It is also important to note that the current shingles vaccine has been 
shown to only reduce the risk of shingles by 50% (Oxman et al., 2005). Because of this, VZV 
continues to be an important public health concern. In order to improve future prevention 
and treatment of VZV infections, a better understanding of VZV’s biology and pathogenesis 
is critical.  
1.2 VZV research methods 
VZV contains the smallest genome among the eight human herpesviruses, consisting of a 
125-kb double-stranded DNA genome that encodes 70 unique open reading frames (ORFs). 
The function of most of these ORFs, however, was largely unknown until recent years. This 
is in part due to the absence of both a genetic tool to efficiently generate mutant clones for 
loss-of-function studies and a true animal model for large scale screening of in vivo virulence 
factors (Cohen et al., 2007).  
Obstacles in mutagenizing VZV include its large genome size, narrow host range, and 
marked differences in replication cycles when studied in vitro versus in vivo (Arvin, 1996; 
Cohen, 2001). A once prevalent technique to create recombinant VZV variants was the four-
cosmid system, made by cloning overlapping segments of the VZV genome into four large 
cosmids (Cohen & Seidel, 1993; Mallory et al, 1997; Niizuma et al., 2003). Co-transfection of 
these cosmids, one of which containing a mutation in the desired ORF, created a 
recombinant VZV variant. However, this method alone faced many challenges. For example, 
research was thwarted because co-transfection of the large cosmids into permissive 
mammalian cells and multiple homologous recombination events within a single cell were 
necessary to generate the full-length viral genome (Zhang et al, 2008). 
More recent developments have helped to circumvent these problems by cloning the entire 
VZV genome as a bacterial artificial chromosome (VZVBAC) (Nagaike et al., 2004). This 
approach provides easy and efficient manipulation of the viral genome and rapid isolation 
of recombinant viruses, making the systemic deletion of every ORF in the genome feasible.  
A firefly luciferase cassette is also inserted into the VZVBAC to produce a novel luciferase 
VZVLuc BAC. This allows us to not only generate VZV ORF deletion mutants, but also 
monitor its subsequent growth in cultured cells.  
2. Generation of a VZVBAC 
Viral BACs are created when a BAC vector sequence is inserted into the viral genome. 
Typically, a BAC vector is roughly 10-kb long and contains an origin of replication, genes 
essential for BAC replication, and genes to control the rate of replication; ideally the copy 
number should be limited to one or two BACs per bacterial cell (Warden et al., 2010). An 
antibiotic resistance marker and selection marker, such as a green fluorescent protein, are 
also added to select for bacterial colonies harboring the BAC vector and isolate these 
BAC-containing recombinant viruses. BAC vectors in addition must also be flanked by a 
500-1000-bp sequence homologous to the target sequence at the site of insertion. Lastly, 
loxP sites are commonly included at both ends of the BAC sequence to excise the vector 
after recombinant viruses are generated, as is required for vaccine production (Zhang et 
al., 2007, see below). 
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2.1 The pUSF-6 vector 
For our purposes, the VZVBAC was constructed from a pUSF-6 vector. As shown in Fig. 1, 
this vector contains the prokaryotic replication origin (ori), replication and partition 
function (repE, parA, parB) genes, chloramphenicol resistance (camr) gene, and a green 
fluorescent protein (GFP) gene. Insertion of a GFP reporter gene in BAC DNA is a popular 
means to visualize in vitro infections in cell culture. Viral GFP is expressed using the SV40 
early promoter and polyadenylation signals, which activate the gene during the 
appropriate stages of viral replication and cause the cell to fluoresce (Marchini et al., 
2001). The vector is also flanked by two 500-bp VZV fragments and contains a loxP site at 
each end (Fig. 1).  
 
Fig. 1. The BAC vector, pUSF-6. The vector contains the prokaryotic replication origin (ori), 
replication and partition (repE, par, and parB) genes, camr gene, green fluorescent protein 
(GFP) gene, two loxP sites and two VZV homologous sequences, a and b. To insert this BAC 
vector into a VZV cosmid, pUSF-6 was digested by BamHI, resulting in a linear fragment. 
2.2 Construction of the VZV BAC (VZVBAC) 
Generally, BAC vectors can be directly inserted into viral genomes via homologous 
recombination. However, this method cannot be used to construct the VZVBAC because the 
virus’ highly cell-associated nature makes isolation of the VZV genome and purification of 
recombinant plaques difficult (Nagaike et al., 2004). Instead, VZVBAC clones are constructed 
using a set of four overlapping cosmids spanning the entire VZV genome (Fig. 2).  
Fig. 2. Schematic diagram the VZV genome and four-cosmid system. The VZV clinical 
strain, p-Oka, consists of a 125-kb genome with unique long (UL) and unique short (US) 
segments. Four cosmids with overlapping VZV genomic segments are shown. The BAC 
vector-containing plasmid, pUSF-6, was inserted between ORF60-61. 
First, the pUSF-6 vector was inserted into VZV cosmid pvSpe23, between ORF60 and ORF61 
(Fig. 2), via homologous recombination (Yu et al., 2000). The BAC-containing cosmid was 
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then co-transfected with three complementary cosmids (Niizuma et al., 2003) into human 
melanoma (MeWo) cells. Because each of the four cosmids contains an overlapping 
sequence, the cosmids can recombine into one large circular virus genome via homologous 
recombination to create the recombinant virus. Our use of the GFP selectable marker in the 
pUSF-6 vector allowed for visualization of the recombinant VZVBAC in plaques that form 
post-transfection (Fig. 3C). Finally, the VZVBAC DNA from the infected cells was purified 
and transformed into E. coli. Chloramphenicol-resistant colonies were selected for and used 
to isolate the desired VZVBAC DNA (Zhang et al., 2007).  
We used restriction enzyme digestion and DNA sequencing to verify the integrity and 
stability of the VZVBAC DNA. VZVBAC DNA was digested by HindIII, yielding the predicted 
digestion pattern with a sum of ~130 kb (Fig. 3G), thus indicating that no large deletions and 
rearrangements were present. In addition, the ORF62/71 gene was sequenced to check for 
base-pair changes in the VZVBAC genome after synthesis in E. coli. This large duplicated 
gene, encoding an immediate-early transactivating protein (Perera et al, 1992), was 
amplified via PCR and cloned into a pGEM-T vector for sequencing. Because the ORF62/71 
sequences in the VZVBAC were identical to those of the published p-Oka strain, we can 
conclude that the BAC DNA in E. coli is stable.  
 
Fig. 3. Construction of VZV BAC. (A) The BAC-containing cosmid was co-transfected with 
the three complementary cosmids into MeWo cells. (B) Homologous recombination between 
cosmids formed a circular, full-length VZVBAC genome. (C) The recombinant BAC was 
replicated, and produced a plaque visualized with the GFP marker. (D) Circular DNA was 
isolated from infected cells, (E) transformed into E. coli, and selected for cmR colonies. (F) 
The VZVBAC DNA was isolated from E. coli and (G) verified by restriction digestion and 
partial sequencing. (H) The infectivity and integrity of the VZVBAC were tested by 
transfecting BAC DNA into MeWo cells to generate the VZV virus.  
The GFP marker in the viral genome was also tested; MeWo cells were infected with 
VZVBAC and continuously passed four times (1:10 dilution) over two weeks. On examination 
of the plaques under a fluorescent microscope, all VZVBAC-infected cells fluoresced green, 
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signifying the stability of the GFP marker in the viral genome. Lastly, the infectivity and 
integrity of the VZVBAC were confirmed by transfecting BAC DNA into MeWo cells to 
produce the virus. A summary of the process to construct a VZV BAC and verify its 
integrity is illustrated in Fig. 3.  
3. Application of VZVBAC with a luciferase marker 
Visualization markers are often inserted into the viral BAC genome to detect and quantify 
viral replication. Two methods frequently utilized are fluorescence imaging and 
bioluminescence imaging. Fluorescence-based imaging, such as through the use of a GFP 
reporter gene, is a common method to monitor in vitro infections and allows researchers to 
study the interaction of a given virus with its host (Tang, 2008). Visualization of in vivo 
infections on the other hand, can be established by the use of bioluminescence imaging (BLI). 
3.1 Background on bioluminescence imaging 
Developed over the last decade, bioluminescence imaging is a technology that enables 
visualization of viral gene expression in live tissues and animals (Tang et al, 2008). With 
little surprise, BLI has become a powerful technique for studying VZV pathogenesis.  
Bioluminescence is the production of light by living organisms, resulting from a chemical 
reaction in which chemical energy is converted to light energy (Hastings, 1983; Kurfurst et 
al., 1983). BLI systems generate bioluminescence using two compounds – luciferase and its 
substrate luciferin. Luciferase is a class of enzymes commonly exploited as a reporter gene 
for transcriptional regulation studies (Doyle et al., 2004). Most extensively employed is the 
luciferase of the North American firefly (Photinus pyralis), which can be expressed in 
mammalian cells by inserting the gene under the control of a promoter. Because firefly 
luciferase generates a bioluminescence wavelength that can efficiently penetrate tissues, it 
serves as an excellent indicator for in vivo studies (Tang et al, 2008). 
There are many advantages to employing BLI over other bio-imaging techniques; one of the 
key factors is its use of luciferin. Not only can luciferin permeate all tissues in vivo (including 
cell membranes and the blood-brain barrier) (Contag et al., 1997; Rehemtulla et al., 2002), the 
substrate can also be administered numerous times to the same animal and provides great 
accuracy, due to its low toxicity and high sensitivity, respectively (Contag et al., 1997; 
Rehemtulla et al., 2000). When exposed to the appropriate luciferin substrate, luciferase will 
catalyze an oxidation reaction to produce light visible to the human eye. The light’s intensity 
depends on the amount of luciferase present, which can be determined by quantifying the 
relative amounts bioluminescence emitted in vivo via computer-based analysis. For this 
reason, engineering viral BACs to express luciferase can be especially valuable for 
monitoring the activities of the promoter that mediates gene regulation, detecting sites of 
viral infections, and quantifying viral replication in living cultures and animals (Zhang et 
al., 2007; Zhang et al., 2008; Dulal et al., 2009; Zhang et al., 2010). 
3.2 The VZVBAC with a luciferase marker (VZVLuc) 
To generate a VZV strain expressing luciferase, a firefly luciferase expression cassette was 
inserted into the intergenic region between ORF65 and ORF66 of the VZVBAC genome. This 
www.intechopen.com
 
Bacterial Artificial Chromosomes 
 
68
clone was transfected into MeWo cells to produce the VZVLuc strain. 24 hours later, cell 
culture media was replaced with media containing 150 µg/ml D-luciferin. After incubation 
at 37°C for 10 minutes, bioluminescent signals were observed and quantified using an In 
Vivo Imaging System (IVIS).  
Upon analysis (Fig. 4), the growth of VZVLuc closely resembled that of its parental VZVBAC 
(data not shown). This confirms that the addition of a luciferase reporter to the viral BAC 
did not change its growth properties. Unlike its parental strain however, only cells infected 
with VZVLuc expressed high levels of luciferase activity (Fig. 4A) and emitted a strong 
bioluminescence after the addition of D-luciferin (Fig. 4B).  
To explore the possibility of using bioluminescent signals as an indicator of viral growth, 
bioluminescent assays were compared to the conventional infectious center assay. Plates were 
inoculated with wild-type (WT) VZV and VZVLuc. Their viral titers were quantified daily via 
both methods for seven days and the data collected was used to construct viral growth curves 
(Fig. 4C). As the figure illustrates, the intensity of the bioluminescent signals strongly 
correlated with the viral titers generated by an infectious center assay. Thus, this data supports 
BLI as an alternative method for growth curve assays and quantifying viral titers. 
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Fig. 4. Analysis of the VZVLuc strain. (A) Luciferase assay. MeWo cells were infected with 
VZVBAC/VZVLuc for two days; luciferase activity was measured. The cells infected with 
VZVLuc showed a high level of luciferase activity, while the parental VZVBAC strain showed 
no activity. (B) Bioluminescence measure. Two wells of MeWo cells were infected with 
VZVBAC (upper left), and two were infected with VZVLuc (upper right). Two days post-
infection, D-luciferin was added to the cultured wells. Bioluminescence was measured and 
could only be detected in VZVLuc-infected cells. The intensities are indicated by an intensity 
scale bar at the top; higher intensities are represented by warmer colors, and lower 
intensities are represented by cooler colors. The infection was verified by the GFP-positive 
plaques (bottom panel). (C) Correlation of luminescence and plaque numbers. Growth 
curves generated by an infectious center assay (black curve and left scale) and a 
bioluminescence assay (green curve and right scale) were compared. 
3.3 Bioluminescence imaging for studying VZV in SCID-hu mice 
Another useful application of bioluminescence imaging is the live-image analysis of VZV 
replication in severe combined immunodeficient mice with human tissue xenografts (SCID-hu 
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mice). Because VZV only infects human cells, in vivo studies of VZV pathogenesis have been 
limited to the use of immunodeficient mice with human tissue implants. However, although 
SCID-hu mice are established as appropriate models for studying VZV pathogenesis (Besser et 
al, 2003; Ku et al., 2005; Zerboni et al., 2005), collecting quantitative data has been a major 
challenge. Since measuring viral growth required the mice to first be euthanized, it was 
impossible to monitor the progression of the viral infection in the same mouse. In addition, 
viral titers tend to vary from animal to animal because of the differently sized implants (Moffat 
& Arvin, 1999), thus hindering not only the frequency of data collection, but also the accuracy 
as well. These factors greatly impeded efforts to study large numbers of VZV variants and 
made it difficult to discern minor phenotypic differences leading to pathogenesis. 
The development of BLI has been extremely helpful to circumvent these obstacles. 
Luciferase provides a visible marker for detecting VZV in human tissues within living 
animals. By using VZVLuc, the SCID thymus-liver mouse model, and In Vivo Imaging System 
(IVIS, Xenogen), the spread of the VZV infection can be frequently monitored in the same 
mouse over an extended period of time; thereby, allowing the generation of credible growth 
curves to gain accurate insights into VZV’s growth kinetics in vivo.  
We applied this method to explore VZV replication and measure its spread in vivo. Human 
fetal thymus and liver tissue were implanted under the left kidney capsule of the SCID 
mouse. Over the course of the next few months, the implanted tissue developed into a 
thymus-like organ consisting mainly of T cells. VZV-infected cells were then inoculated into 
the SCID-hu mice with thymus-liver implants. VZV replication was measured in vivo after 
the injection of the luciferin substrate, using an IVIS. Each mouse was imaged daily, starting 
four hours after inoculation (i.e day zero), for eight days (Fig 5A).  
Our data depicts the daily increase in bioluminescence emitted from the infected implants 
(Fig. 5B). The quantified signals were plotted to generate an in vivo growth curve (Fig. 5C). 
As shown, VZV grew rapidly in human T cells, doubling approximately every 12 hours and 
peaking at seven days postinfection. The exponential growth curve is then followed by a 
steady state where the viral infection reaches the saturation limit of the implant. 
We also tested the VZVLuc viruses for their spread and detection in human fetal skin 
xenografts in vivo. Similar to the process outlined above, human skin tissues were 
introduced into SCID mice. Four weeks after implantation, VZVLuc virus was inoculated into 
the skin tissues and viral growth was monitored every two to three days for 15 days using 
an IVIS. High luciferase activity was detected in the implants (data not shown), verifying 
VZVLuc’s ability to grow in skin tissue in vivo.  
In short, by engineering VZV to express luciferase enzymes, bioluminescence imaging can 
be used to monitor the progression of viral growth and quantify viral replication in organ 
cultures and SCID-hu mice. Compared to the traditional infectious center assay, BLI not 
only saves time and labor, but also significantly increases the reproducibility of results 
(Doyle et al., 2004). Moreover, the presence of luciferase activity indicates viral replication in 
cells and not free-viral particles (Zhang et al., 2010), making BLI the most suitable method 
for studying this particular cell-associated virus. Consequently, the development of BLI has 
greatly facilitated our ability to investigate aspects of VZV infection in the SCID-hu mouse 
model and has significantly advanced our understanding of VZV pathogenesis and virus-
cell interactions (Zerboni et al., 2010; Arvin et al, 2010; Zhang et al; 2010; Moffat & Arvin; 
1999; Arvin, 2006).  
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Fig. 5. Monitoring VZVLuc virus replication in SCID-hu mice. (A) SCID-hu model. 1. Human 
fetal thymus/liver tissues were implanted under SCID mouse kidney capsule. 2. Two to 
three months later, the implant was inoculated with VZVLuc. 3. Viral replication in human T 
cells was detected by IVIS. (B) Replication and progression of VZVLuc in human 
thymus/liver implants in SCID mice. Three SCID-hu mice with thymus/liver implants were 
inoculated with VZVLuc. Using IVIS, each mouse was scanned daily (from day 0 to day 8). 
Measurements were taken 10 minutes after i.p. injection with luciferin substrate. Only 
images from one mouse are shown. Warmer colors indicate higher viral load; colder colors 
indicate lower viral load. (C) VZV growth curves in vivo.  Bioluminescence from three SCID-
hu mice in the above experiment (B) was measured and VZV growth curves in human 
thymus/liver implants were generated. 
4. Generation of recombinant VZV using a highly efficient homologous 
recombinant system 
To test the novel VZVLuc system for studying VZV pathogenesis, five single ORF deletion 
mutants were first generated, starting from ORF0 to ORF5, via the homologous 
recombination system harbored in DY380 E. coli. Afterwards, the VZVLuc was used for 
genome-wide mutagenesis to systematically delete each individual VZV ORF for functional 
characterization of the VZV genome. 
4.1 The DY380 E. coli strain 
The DY380 E. coli strain offers a highly efficient homologous recombination system for 
chromosome engineering by enabling efficient recombination of homologous sequences as 
short as 40-bp (Yu et al., 2000). A defective lambda prophage supplies the function that 
protects and recombines linear DNA. In addition, the system is strictly regulated by a 
temperature-sensitive lambda repressor. This allows homologous recombination between 
two sequences to be transiently induced by activating the prophage through incubation at 
42°C for 15 minutes.  
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4.2 Generation of a VZV deletion clone 
The entire process to engineer a VZV ORF deletion mutant (ORFXD) is illustrated in Fig. 6. 
VZVLuc BAC DNA was first introduced into DY380 by electroporation. Homologous 
recombination functions were transiently induced by increasing the culturing temperature 
to 42°C for 15 minutes during electroporation-competent cell preparation. A kanR expression 
cassette was amplified from pGEM-oriV/kanR by PCR using two primers containing 40-bp 
homologous sequences flanking the target ORF (ORFX). The PCR product was then 
transformed into the DY380 harboring the VZVLuc BAC via electroporation. As expected, 
homologous recombination occured between the ORF flanking sequences of the cassette and 
targeted ORF, replacing the ORFX with the kanR gene and generating an ORFXD VZV clone 
(Zhang et al., 2008).  
 
Fig. 6. Generation of a VZV deletion clone. (A) The DY380 strain permits transient induction 
of recombination system by incubation at 42°C for 15 min during electro-competent cell 
preparation. VZVLuc BAC DNA was introduced into DY380 by electroporation. (B) 
Amplification of the kanR expression cassette by PCR using a primer pair to add 40-bp 
homologous sequences flanking ORFX. (C) 200ng of the above PCR product was 
transformed into DY380 carrying the VZVLuc BAC by electroporation. (D) Homologous 
recombination between upstream and downstream homologies of ORFX replaced ORFX 
with the kanR cassette, creating the ORFX deletion VZV clone. (E) Recombinants were 
selected on LB agar plates. (F) The deletion of ORFX DNA was isolated and confirmed by 
testing antibiotic sensitivity and PCR analysis. The integrity of the viral genome after 
homologous recombination was examined by restriction enzyme digestion. (G) Purified 
BAC DNA was transfected into MeWo cells. (H) 3-5 days after transfection, the infected cells 
were visualized by fluorescence microscopy. 
Successful ORF deletion clones were confirmed by three sequential procedures: 1. antibiotic 
sensitivity selection, 2. mini-preparation of BAC DNA with PCR verification, and 3. maxi-
preparation of BAC DNA with HindIII digestion profiling. Firstly, recombinants were selected 
on LB plates with chloramphenicol or kanamycin for resistant colonies. It was also important 
to verify that the deletion clones were sensitive to ampicillin since ampicillin-resistant circular 
pGEM-oriV/kanR was used as the PCR template. Multiple colonies were then selected for 
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mini-preparation of BAC DNA to confirm the ORF deletion and kanR replacement by PCR. 
Lastly the PCR-verified clones were chosen for maxi-preparation of BAC DNA and digested 
with HindIII to ensure that only the targeted sequence was deleted. When the digestion 
pattern of the deletion clone was compared to that of the parental WT VZVLuc clone, no 
additional deletions from the genome were detectable (as shown in Fig. 3G).  
Finally, to generate VZV deletion mutant viruses, these verified clones were transfected into 
MeWo cells, along with WT VZVLuc DNA. The size and growth kinetics of the virus as 
measured by resultant plaques, or absence of plaques, are indicative of the essentiality of a 
particular VZV ORF for viral replication, discussed later. 
4.3 Generation of a VZV rescue clone 
VZV ORF deletion rescue clones were also generated (Fig. 7) in order to show that growth 
defects observed in analyses of the deletion mutants are a direct result of the deleted genes, 
as opposed to potential mutations in other regions of the genome. Ideally, the wild-type 
phenotypes should be fully restored in these rescue viruses. 
 
Fig. 7. Generation of a VZV rescue clone. (A) ORFX was amplified by PCR from the WT 
VZV BAC DNA and (B) directionally cloned into plasmid pGEM-lox-zeo to form pGEM-lox-
zeo-ORFX. (C) Amplification of the ORFX-zeoR rescue cassette by PCR using a primer pair 
adding 40-bp homologies flanking ORFX. (D) The PCR product was transformed into DY380 
carrying the VZVLuc ORFX deletion via electroporation. (E) Homologous recombination 
between upstream and downstream homologies of ORFX replaced kanR with the ORFX-zeoR 
rescue cassette. (F) ZeoR and BAC vector sequences were removed post-verification by co-
transfecting a Cre recombinase-expressing plasmid, creating the ORFX rescue clone. 
To generate ORF deletion rescue clones (ORFXR), the targeted ORF deletion was amplified 
from wild-type VZVLuc BAC DNA by PCR. Next, the ORFX was directionally cloned into 
plasmid pGEM-lox-zeo to produce pGEM-zeo-ORFX. This was then used as the template to 
generate the ORFX-zeoR cassette via PCR using a primer pair to add 40-bp sequences, 
homologous to the kanR cassette flanking ORFX. In a process similar to the homologous 
recombination system described earlier, the PCR product was transformed into DY380 
carrying the ORFX deletion genome (Fig. 7C). The kanR cassette was replaced with the 
ORFX-zeoR rescue cassette by homologous recombination, thus allowing for positive 
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selection of zeocinR colonies. Because the zeoR gene within the rescue cassette is flanked by 
two loxP sites, it can be removed along with the BAC vector, through Cre-mediated 
recombination, generating the desired ORFX rescue virus. Full recovery from the marked 
growth defects is expected after using this rescue method to restore the wild-type ORF.  
5. Functional profiling of VZV genome 
Even though VZV has the smallest genome among all human herpesviruses, less than 20% 
of the VZV genome had been functionally characterized (Cohen et al, 2007). In order to 
investigate VZV ORF function, we created an entire library of single VZV ORF deletion 
mutants using the DY380 E. coli recombination system. The individual functions of each 
ORF were determined by transfecting MeWo cells with mutant DNA, and observing the 
subsequent growth of viral plaques. If a VZV ORF is nonessential for viral replication, 
plaques corresponding to the deleted ORF should be detectable 3-5 days after transfection 
and resemble the growth of the wild-type virus. Plaques that grow significantly smaller and 
later suggest that the ORF strongly influences optimal growth. The absence of a plaque 
entirely implies that the ORF is essential for viral replication. 
5.1 Essential VZV ORFs 
The results indicate that among VZV’s 70 unique ORFs, 44 ORFs are essential for viral 
replication in cultured MeWo cells, while 26 ORFs are nonessential (Zhang et al., 2010). Fig. 
8 provides a visual representation of the entire VZV genome and categorizes the essentiality 
of each ORF based on the growth properties of its corresponding deletion mutant virus.  
 
Fig. 8. VZV genome-wide functional profiling based on analysis of single viral ORF deletion 
mutants. Each VZV ORF is color-coded according to the growth properties of its 
corresponding virus gene-deletion mutant in cultured MeWo cells and human fetal skin organ 
cultures. The grey lines for ORF42 represent a splicing junction. For all growth curves, wild-
type infections served as positive controls and mock infections served as negative controls. 
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Various studies, cumulatively, have found that the essential VZV ORFs encode genes for 
viral structural proteins, transcriptional regulatory proteins, and enzymes involved in 
DNA replication. The majority of these crucial ORFs encode proteins with imperative 
functions in maintaining the viral life cycle. For example, some ORFs are a part of the 
viral tegument and encode immediate-early proteins with transcriptional regulatory 
activity (Perera et al., 1992; Defechereux et al., 1993; Moriuchi et al., 1994). Other ORFs 
encode phosphoproteins primarily contained in the nuclei of infected cells (Moriuchi et 
al., 1993). It has also been reported that most of the VZV ORFs encoding glycoproteins 
also belong in this group of genes indispensable for viral replication (Mallory et al., 1998; 
Yamagishi et al., 2008). 
Upon further analysis, we found that essential VZV genes have significantly different 
enrichment for functional categories than nonessential genes. As depicted by the 
distribution of functional annotations (Fig. 9A), essential VZV genes are significantly 
enriched for DNA replication and DNA packaging. These include genes encoding the 
subunits of VZV DNA polymerases, DNA binding proteins, DNA packaging proteins, and 
nucleocapsid proteins. 
5.2 Nonessential VZV ORFs 
As previously mentioned, 26 of the 70 unique VZV ORFs were deemed nonessential for 
VZV replication in MeWo cells (Zhang et al., 2010). Of these, 8 ORFs appeared to 
significantly affect viral growth. In viral growth assays, the peak signals from their 
corresponding plaques were at least 5-fold less than the peak signals from the WT parental 
strain. Furthermore, atypical morphology of virally infected cells, such as reduced plaque 
sizes and altered syncytia formation, were also frequently observed. Studies have shown 
that some of these ORFs affecting optimal growth encode the small and large subunit of 
ribonucleotide reductase (Heineman & Cohen, 1994) and specific phosphoproteins that are 
post-translationally modified by protein kinases (Reddy et al., 1998). 
The plaques corresponding to the remaining 18 nonessential VZV ORF deletions exhibited 
wild-type growth in cultured MeWo cells (Zhang et al., 2010). In vitro growth curve analysis 
for viral replication showed that these ORF deletion mutants have the same growth kinetics 
as their wild-type parental strain, VZVLuc. Nonessential genes, in general, are significantly 
enriched for other and unknown functional categories (Fig. 9B). 
5.3 Other findings 
Despite major differences between herpesvirus genomes, all the herpesviruses studied 
thus far have a similar number of essential genes, but varying number of nonessential 
genes. For example, our study suggests that the VZV genome encodes 44 essential genes 
and 26 nonessential genes. The herpes simplex virus 1 (HSV-1) genome encodes 37 
essential genes and 48 nonessential genes (Roizman et al., 2007). Similarly, the human 
cytomegalovirus (HCMV), one of the largest human DNA viruses, has a genome that 
encodes 45 essential genes and 118 nonessential genes (Dunn et al, 2003). Furthermore, 26 
of the 44 essential VZV genes have essential homologues in HSV and 18 of the 44 have 
essential gene homologues in HCMV, alluding that some essential genes may perform 
core functions for all of these herpesviruses.   
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Another observation worth noting is the size of the essential ORFs as compared to the size 
of the nonessential ORFs. Essential ORFs are significantly larger in size, averaging 1250-bp, 
while nonessential ORFs have an average size of 970-bp. Moreover, the ten largest VZV 
ORFs are all essential, while of the 11 smallest VZV ORFs, eight are nonessential.  
 
Fig. 9. Distribution of functional annotations for essential and nonessential genes. (A) 
Distribution of functional annotations for essential genes. Essential genes are significantly 
enriched for DNA replication (Bonferroni corrected p-value <10-4) and DNA packing 
(corrected p-value <10-4) functional categories. (B) Distribution of functional annotations for 
nonessential genes. Nonessential genes are significantly enriched for other (corrected p-
value <10-3) and unknown (corrected p-value <0.01) functional categories. Statistical 
significance was determined by a hypergeometric test.  
6. Identification of VZV tissue tropic genes  
Although 26 VZV ORFs are shown to be dispensable for viral replication in cultured MeWo 
cells, it is possible that some of these viral genes may encode proteins critical for optimal 
viral infection in skin tissue. To test this hypothesis, all of the nonessential ORF deletion 
mutants were further tested in human fetal skin organ culture (SOC). SOC is a reliable 
alternative to the SCID-hu mouse model (Taylor & Moffat, 2005), and is especially 
convenient for initial genome-wide screening of skin-tropism determinants. 
We found that all VZV deletions which demonstrated severe growth defects in cultured 
MeWo cells also exhibited the same growth defects in SOC samples. Interestingly however, 
among the 18 VZV ORFs believed to be completely dispensable for viral replication in 
cultured MeWo cells, four ORFs displayed significant growth defects in SOC  (Fig. 8) 
(Zhang et al., 2010). Because these ORFs are trivial for viral replication in MeWo cells but 
prove crucial for optimal viral replication in skin tissue, they evoked further investigation as 
potential skin tropism factors. 
Rescue viruses were generated for two of these four ORF deletions to ensure that growth 
defects in skin culture are in fact due to the functions of the deleted genes. As expected, the 
growth curve analyses showed that in MeWo cells, rescue viruses grew indistinguishably 
from wild-type VZV, and in SOC, they were able to fully recover the growth defects of their 
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corresponding deletion mutants (Zhang et al., 2010). Three of these four ORFs (ORF10, 
ORF14, ORF47) have previously been identified as tissue-tropic factors (Cohen & Seidel, 
1994; Heineman & Cohen, 1995; Moffat et al., 1998). Our findings verified these previous 
studies and additionally identified ORF7 as a novel skin-specific virulence factor. To 
confirm our original finding here, we also produced a premature stop-codon mutant 
(ORF7S) by mutating the 5th codon from TGT to the TGA stop codon. Like ORF7D, ORF7S 
displayed wild-type growth in MeWo cells, but had a growth defect in SOC, indicating that 
ORF7 may function as a VZV skin-tropic factor. 
7. Ongoing research 
As mentioned previously, after a primary VZV infection, the virus will remain dormant in 
the sensory ganglia of its host. When reactivated, VZV will erupt from the sensory neurons 
and infect surrounding skin tissue, causing characteristic rashes and severe pain due to 
nerve damage. Therefore, identifying the VZV factors responsible for not only skin-tropism, 
but also neurotropism is of great importance.  
7.1 Screening for VZV neurotropic factors 
We proposed that the VZV genome also encodes factors required for efficient invasion and 
egress from specific tissues during natural infection, such as neurotropic factors. Using our 
newly created VZV deletion mutants, we screened each of the 18 dispensable VZV ORFs to 
determine which are implicated with VZV neuronal infection. First, the mutant DNAs were 
confirmed to be replication competent in a primary permissive cell line, the human retinal 
epithelial ARPE19 cells (Schmidt-Chanasit et al., 2008). Then, the deletion mutants were 
screened in human neuroblastoma, SH-SY5Y, following a similar transfection approach as 
described earlier for MeWo cells, to establish their essentiality for replication in human neurons. 
Of the mutants tested, only the ORF7 deletion mutant was unable to form viral plaques 
(data not yet published). To confirm this, we also infected differentiated neuroblastoma and 
human embryonic stem cell-derived neurons with wild type and 7D cell-free particles. As 
expected, the WT infection exhibited robust proliferation, while the 7D infection yielded no 
visible plaques. Our finding here establishes ORF7 as the only known VZV factor required 
for viral spread in human neurons. 
7.2 Future applications 
While the current VZV vaccine is sufficient to prevent chickenpox, many issues still 
surround this live attenuated vaccine. Firstly, bulk vaccine production using the vOka strain 
is difficult and costly due to vOka virus’s relatively low yield (Schmid & Jumaan, 2010; 
Gomi et al, 2002). The vaccine is also not entirely effective at eliminating chickenpox 
outbreaks. Despite seroconversion after vaccination, varicella infections still occur in some 
children and adults exposed to wild-type VZV (Schmid & Jumaan, 2010; Bernstein et al., 
1993, White et al., 1991). Most significantly however, the currently marketed vaccine strain, 
v-Oka, while highly attenuated in the skin, still retains its neurovirulence (Hambleton et al., 
2008). This means that the virus will continue to establish latency in the sensory nerve 
ganglia of the immunized host and can potentially reactivate later to trigger herpes zoster 
and post-herpetic neuralgia. Furthermore, while drug treatments available to date can 
alleviate some symptoms of VZV-elicited diseases and shorten the disease duration, they 
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cannot clear the virus or prevent establishment of latency (Miwa et al., 2005; Hatchette et al., 
2008). For these reasons, developing a new neuro-attenuated vaccine is imperative to 
prevent future herpes zoster in both elderly people and vaccinated children.  
The use of viral BACs has great potential for novel vaccine development and future 
treatment of viral diseases. Our studies using the VZVLuc BAC uncovered the first, and 
plausibly the only, VZV neurotropic factor, ORF7. Because the ORF7D strain is incapable of 
infecting both human skin and nervous tissue in vivo, the deletion virus may serve as an 
ideal vaccine candidate for the next generation of chickenpox and shingles vaccines. Aside 
from using the ORF7 deletion virus to produce a safer neuro-attenuated vaccine for the 
prevention of herpes zoster, the same deletion virus may also be utilized as a potential viral 
vector for the production of vaccines against other pathogens as well. 
Additional research into this BAC-based candidate is needed to lead us closer to designing 
neuro-attenuated vaccines that do not establish latency in sensory neurons, and thereby 
eliminate the risk of recurrent herpes zoster and its complications. In time, the development 
of safe and effective neuro-attenuated vaccines will decrease the likelihood of herpes zoster 
in the contemporary susceptible population, reduce herpes zoster-associated costs, and 
potentially eradicate VZV and VZV-related diseases (Lydick et al., 1995; Drolet et al., 2010). 
Essentially, these new vaccines will change the future of VZV altogether. 
8. Conclusions 
The use of a bacterial artificial chromosome system has proven to be an invaluable tool in 
human herpesvirus studies, without which, our genome-wide VZV mutagenesis could not 
have been possible. Not only can BACs clone the large viral genomic DNA, their slow 
replication rate and relative ease and accuracy of producing and reproducing stable viral 
mutants make BACs the ideal method for functional analysis of the VZV genome. 
Furthermore, the addition of a luciferase marker has greatly improved the efficiency, accuracy 
and reproducibility of our results. Combined, this luciferase BAC approach has truly 
facilitated genetic studies of VZV and provided vital insights into the replication and 
pathogenesis of the virus. 
In this study, a global functional analysis of the entire VZV genome was carried out, 
focusing on the identification of ORFs essential for viral replication in cultured MeWo cells 
and human fetal skin organs. In all, our study has distinguished novel functional 
annotations for 36 VZV genes and shed light on the essentiality of each of the 70 unique 
VZV ORFs. More importantly, our findings have identified ORF7 as both a skin-tropic and 
neurotropic factor, implicating the ORF7 deletion virus as an ideal vaccine candidate to 
prevent both VZV-elicited diseases, chickenpox and shingles. 
As our research progresses, future VZVLuc BAC studies will continue to provide more exciting 
discoveries and help identify new antiviral targets. Soon, effective vaccines and improved 
therapy for the prevention and treatment of a wide array of infections will be tangible. 
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